The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naïve hepatitis C patients. - Wikidata - thesis-toulmin - TriplyDB

The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naïve hepatitis C patients.

The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naïve hepatitis C patients.

http://www.wikidata.org/entity/Q48033815

about

Cyclosporin A associated helicase-like protein facilitates the association of hepatitis C virus RNA polymerase with its cellular cyclophilin B A host YB-1 ribonucleoprotein complex is hijacked by hepatitis C virus for the control of NS3-dependent particle production Chaperones in hepatitis C virus infection Chronic hepatitis C: This and the new era of treatment Chronic Hepatitis C Infection in Children: Current Treatment and New Therapies Curing a viral infection by targeting the host: the example of cyclophilin inhibitors Review article: HCV genotype 3 – the new treatment challenge Emerging therapies for the treatment of hepatitis C Future classes of hepatitis C virus therapeutic agents Cyclophilin Inhibitors Remodel the Endoplasmic Reticulum of HCV-Infected Cells in a Unique Pattern Rendering Cells Impervious to a Reinfection A genome-wide genetic screen for host factors required for hepatitis C virus propagation Hepatitis C: recent successes and continuing challenges in the development of improved treatment modalities Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment Elucidating novel hepatitis C virus-host interactions using combined mass spectrometry and functional genomics approaches Infection Counter: Automated Quantification of in Vitro Virus Replication by Fluorescence Microscopy A new stochastic model for subgenomic hepatitis C virus replication considers drug resistant mutants Characterization of the Anti-HCV Activities of the New Cyclophilin Inhibitor STG-175 DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond Fragment-based discovery of a new family of non-peptidic small-molecule cyclophilin inhibitors with potent antiviral activities Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II).Both Cyclophilin Inhibitors and Direct-Acting Antivirals Prevent PKR Activation in HCV-Infected Cells.A major determinant of cyclophilin dependence and cyclosporine susceptibility of hepatitis C virus identified by a genetic approach Glycogen synthase kinase 3β inhibitors prevent hepatitis C virus release/assembly through perturbation of lipid metabolism Current and future therapies for hepatitis C virus infection.Productive hepatitis C virus infection of stem cell-derived hepatocytes reveals a critical transition to viral permissiveness during differentiation.Hepatitis C virus experimental model systems and antiviral drug research.Profile of alisporivir and its potential in the treatment of hepatitis C.Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C.Potential treatment options and future research to increase hepatitis C virus treatment response rate Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C.A translation inhibitor that suppresses dengue virus in vitro and in vivo Cyclophilin and NS5A inhibitors, but not other anti-hepatitis C virus (HCV) agents, preclude HCV-mediated formation of double-membrane-vesicle viral factories The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action.Roles of Prolyl Isomerases in RNA-Mediated Gene Expression Cyclosporin A inhibits the replication of diverse coronaviruses Treating hepatitis C infection by targeting the host.Hepatitis C virus-host interactions, replication, and viral assembly Correlation of naturally occurring HIV-1 resistance to DEB025 with capsid amino acid polymorphisms Anti-HCV drugs in the pipeline.

P2860

Q21135500-18C86A74-7F39-4A92-87D0-67D2F72AA14E Q24320237-C2783AAE-3ADE-4405-ACC1-BFD665434D5A Q26771251-25330577-4DFE-41FA-89D1-D0C231832B30 Q26775011-B56D7C31-9468-45B6-93BE-8200504C5ABA Q26781770-44DAF589-62C7-4043-B7DA-3D1EF568DE4D Q26828727-6F8A013E-3BEC-4160-B53D-053F196DA21D Q26864571-CB09E7A3-BB83-4C28-A21C-BEF616540197 Q27003319-26A61657-D839-46DE-86F2-CF2639EF554F Q27009321-41A3286E-517A-4939-8F31-D2582B7AB434 Q27468931-ACC13652-7FA9-414F-A3EA-0F6A3C518C1C Q27489773-B9D8620B-5E80-4ADD-B4C1-CEC3D8397B07 Q27490426-1F6C1A94-CCDD-40C4-B980-7DB7DB28046F Q27490974-9F3A42A6-D357-4E88-B358-D75EBE7E43BB Q28115639-02C6DC49-EBFE-49AC-A82E-8EF0C97B2FE0 Q28364857-BBC3E8FC-43FC-4FAB-AA9D-4BD523C251E9 Q28541048-11B5D321-5456-450B-BE6C-2BE0218EFE9F Q28551538-3B735173-0F2E-453C-B554-3C4F101FC8CF Q28748683-16C781B4-C5C1-4832-8F8F-5C87EF49587D Q29994527-E4E55D84-B7BF-4746-A070-A76A72FFB7C0 Q31132161-FFD0D1F5-34AF-4720-B527-2BA2900F2958 Q33424900-BCEBF6C7-035B-4996-822D-1579BC12FFE8 Q33565080-82591BCE-10CF-4E36-9FA0-981982B5E5B3 Q33707739-97F05313-F6AC-44F3-9AD6-A6C7C0A00BCB Q33747040-0E363136-326D-42EA-A0AA-56D7EA056433 Q34036762-2964A9A1-96C5-4E93-A7BB-862B3EEE8B1E Q34229606-5CC6C092-592B-418A-977D-F6C1469AE61C Q34235286-38584605-6B00-46BD-BC11-0830BD031090 Q34329744-3B3B0E41-5998-4D08-B1EF-51ED94795C10 Q34489239-7F15BD06-DD32-44C7-AFAF-4E9DB3C158E3 Q34576190-53376F63-1A0C-4C16-9844-02AE4E24E5FC Q35135565-DDCF0021-62C1-4CDF-B826-7D87DC3E1C9B Q35191440-494D3F78-2D10-4C1C-B3E1-5B2C06676CE6 Q35385005-07C82D65-ECCE-4A2D-A651-D1947BE82AC2 Q35742761-B71B6C93-80C3-423F-9435-30D729E0E8A6 Q35834035-6861D1AD-02FE-4154-BB4F-DC517B7B0E1A Q35960586-D385DE16-A688-40BC-9C1E-2F1EAA214D7D Q35992555-BE5857D3-AB0E-460B-B7EB-043F040307A6 Q36427976-B8FF89DA-43FC-4F32-BC80-EB9F89B64EDF Q36993953-8D0D5FC4-D60C-4878-90C0-8C192E9C2372 Q37177740-C2AB9562-0115-4F24-9D8F-7FD0774E0695

P2860

The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naïve hepatitis C patients.

http://www.wikidata.org/entity/Q48033815

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

The cyclophilin inhibitor Debi ...... nt-naïve hepatitis C patients.

@en

The cyclophilin inhibitor Debi ...... nt-naïve hepatitis C patients.

@nl

type

label

The cyclophilin inhibitor Debi ...... nt-naïve hepatitis C patients.

@en

The cyclophilin inhibitor Debi ...... nt-naïve hepatitis C patients.

@nl

prefLabel

The cyclophilin inhibitor Debi ...... nt-naïve hepatitis C patients.

@en

The cyclophilin inhibitor Debi ...... nt-naïve hepatitis C patients.

@nl

P1433

Q48033815-48A3F5C4-425B-4610-99D9-6892AB74E0B2

P1476

Q48033815-75400C17-33F0-4D4F-A55E-579E6895A4B1

P2093

Q48033815-0EE956A7-2B9E-475B-82CE-F66542EC7AD3

Q48033815-234D235B-2E74-459C-B13D-C427C6E7E251

Q48033815-2877AE66-3AF7-47F9-857F-1BAC7C38231F

Q48033815-382F214D-929C-4E52-AA46-E2375C22A18A

Q48033815-43F037EA-5D44-4943-A536-6356ACBB7C7A

Q48033815-475B973C-BB79-44FB-9478-116314942329

Q48033815-52595819-C995-4778-AED6-9317653E0E4D

Q48033815-8EA68766-AC0A-442F-86A6-E4368A0CA92B

Q48033815-944350DF-F0BC-41D3-B4CA-143ACB40C48D

Q48033815-B519FD4F-BE98-4A00-9E9D-A115BE11B7DB

P2860

Q48033815-05911E50-04E0-4ABB-87EC-744F68E590E4

Q48033815-33D0623C-DD30-49D0-893F-A98490FE54B0

Q48033815-38E7E78D-3E13-4770-A889-C46C6B6D2683

Q48033815-4510894D-1482-47B5-8E45-93664C5FF07F

Q48033815-521F60DA-AD24-4E39-8743-AE918D67058C

Q48033815-5CBD5F3B-3858-4478-9E50-3C9C342A4573

Q48033815-6025855C-85BA-4093-B155-9317034A12EF

Q48033815-6697CFB3-52C7-4872-A75B-D7243CF593F5

Q48033815-7AD5897B-F8B0-4F86-827A-4C2F8DED0F89

Q48033815-96B49E4B-6EA9-42FE-95AE-36DBC8B4BDDC

P304

Q48033815-35CA0F07-18AA-444E-871A-857D2DAEB807

P31

Q48033815-C6010D59-02B4-4D3D-AF36-E276780F8A19

P356

Q48033815-008E6868-364B-47C7-8A3D-F6042A5BD914

P407

Q48033815-E5FABFCD-5A87-4E07-BCD2-2AC5B6919791

P433

Q48033815-0ABC420E-4823-4CD5-A2D0-1AD79B193204

P478

Q48033815-6358EFFA-9706-4374-8808-C6A4304D3F9A

P50

Q48033815-302BECD3-0B4D-4F1B-86A5-02D573E1E520

Q48033815-48D5AB57-02E8-4407-A5FA-D215E17A5211

Q48033815-676EA6B6-7F2B-4770-B359-FE6A7051D868

Q48033815-AD3ACDBE-DF8F-48EB-9BAB-3566C8EC5FFA

P577

Q48033815-B35F612C-5B94-4306-83DD-0DE2B0D6CD85

P5875

Q48033815-47020A58-07CA-4166-A37E-1653582EF3F5

P698

Q48033815-581775ED-AD47-4F61-8EB9-9E634E752330

P921

Q48033815-10D7D6E2-E502-4EF4-890A-23A69EAFCDE7

Q48033815-4A3FBCA4-4A4E-4AEC-9A0E-296980651D4D

P356

P1433

P1476

The cyclophilin inhibitor Debi ...... ent-naïve hepatitis C patients

@en

P2093

Andrzej Horban

http://www.w3.org/2001/XMLSchema#string

Hervé Porchet

http://www.w3.org/2001/XMLSchema#string

Jenny E Heathcote

http://www.w3.org/2001/XMLSchema#string

Jorge S Liz

http://www.w3.org/2001/XMLSchema#string

Maciej Jablkowski

http://www.w3.org/2001/XMLSchema#string

Pierre Grosgurin

http://www.w3.org/2001/XMLSchema#string

Pietro Scalfaro

http://www.w3.org/2001/XMLSchema#string

Raf Crabbé

http://www.w3.org/2001/XMLSchema#string

Saya V Feinman

http://www.w3.org/2001/XMLSchema#string

Valérie Nicolas-Métral

http://www.w3.org/2001/XMLSchema#string

P2860

Epidemiology of hepatitis C virus infection

Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase

Hematologic side effects of interferon and ribavirin therapy.

CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects.

The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro.

A comparison of the effect of ciclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients.

American Gastroenterological Association technical review on the management of hepatitis C.

Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins.

Interferons alpha, beta, gamma each inhibit hepatitis C virus replication at the level of internal ribosome entry site-mediated translation.

Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo.

P304

1460-1468

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.22835

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P50

Giuseppe Mazzella

Malgorzata Pawlowska

Carmen Vandelli

P577

2009-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24264136

http://www.w3.org/2001/XMLSchema#string

P698

19353740

http://www.w3.org/2001/XMLSchema#string

P921